Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · people with sickle cell disease
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing new or progressive SCI lesions · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
1 finding from 1 review
All‐cause mortality · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
SCD ‐ related SAEs ‐ ACS · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
It is very uncertain whether hydroxyurea changes SCD‐related SAEs ‐ ACS compared with RBC transfusions (very low certainty).
1 finding from 1 review
SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
It is very uncertain whether hydroxyurea changes SCD‐related SAEs ‐ pain crisis compared with RBC transfusions (very low certainty).
1 finding from 1 review
Stroke · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
1 finding from 1 review
Cognitive function ‐ not reported · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · prevention of SCI in people with SCD who have not had a stroke (primary prevention)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing new or progressive SCI lesions · prevention of SCI in people with SCD who had a stroke (secondary prevention)
It is very uncertain whether hydroxyurea changes proportion of participants developing new or progressive SCI lesions compared with RBC transfusion (very low certainty).
1 finding from 1 review
All‐cause mortality · prevention of SCI in people with SCD who had a stroke (secondary prevention)
It is very uncertain whether hydroxyurea changes all‐cause mortality compared with RBC transfusion (very low certainty).
1 finding from 1 review
SCD ‐ related SAEs ‐ ACS · prevention of SCI in people with SCD who had a stroke (secondary prevention)
It is very uncertain whether hydroxyurea changes SCD‐related SAEs ‐ ACS compared with RBC transfusion (very low certainty).
1 finding from 1 review
SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD who had a stroke (secondary prevention)
Hydroxyurea may leads to higher SCD‐related SAEs ‐ pain crisis compared with RBC transfusion (low certainty).
1 finding from 1 review
Stroke · prevention of SCI in people with SCD who had a stroke (secondary prevention)
It is very uncertain whether hydroxyurea changes clinical stroke compared with RBC transfusion (very low certainty).
1 finding from 1 review
Cognitive function ‐ not reported · prevention of SCI in people with SCD who had a stroke (secondary prevention)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · prevention of SCI in people with SCD who had a stroke (secondary prevention)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found